drug
Kimyrsa
Marketedupdated 4mo agoby Melinta Therapeutics LLC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying Kimyrsa
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 29, 2029
~3.0 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Jul 16, 2035compositionUS 9649352
- Apr 26, 2030method-of-use (U-3101)US 96820613.7y
- Aug 29, 2029method-of-use (U-4398)US 125148993.0y
- Aug 29, 2029method-of-use (U-3101)US 84205923.0y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2m ago
Found something off?
comments(0)
5-min edit window · permanent after that